Cardiovascular disease |
Ahmed, 200717 | Digoxin | 2471 (63.8 years) | NR | NR | NR |
Kutner, 201537 | Statins | 381 (74.1 years) | 91 (48.1) | 0 | Intervention: 7 (3.7) Control: 3 (1.6) |
Lemos, 201438 | Oral nitrates | 105 (61.5 years) | 50 (98.0) | NR | Intervention: 1 (2.0) Control: 5 (9.3) |
Lewin, 201220 | Nebivolol | 207 (52.7 years) | 101 (96.2) | 2 (1.9) stopped study medication | Intervention: 4 (3.8) Control: 3 (2.9) |
Moonen, 201522 | BB, diuretic, ACEI, ATII-blocker, CCB, or combination | 356 (81.3 years) | 199 randomised, 180 analysed (90.5) | NR | Intervention: 19 (10.6) Control: 10 (5.7) |
Moonen, 201630 | Diuretic, BB, AT blocker, ACEI, CCB | 162 (81.0 years) | 46 (53.5) complete stop 21 (24.4) partial stop | 10 (11.6) restarted or needed additional medication | NR |
Psychiatric and behavioural disorders |
Ballard, 200931 | Risperidone, haloperidol, and other antipsychotics | 165 (84.9 years) | 33 (51.6) | 7 (10.9) restarted antipsychotics after minimum of 12 months placebo | Intervention: 41 (64.0) Control: 50 (78.1) |
Bergh, 201232 | SSRIs | 128 (85.7 years) | 35 (55.5) | Intervention: 13 (20.6) Control: 4 (6.2) (SD) | Intervention: 28 (44.4) Control: 19 (29.2) |
Devanand, 201116 | Haloperidol | 20 (NR) | 2 (20.0) | Intervention: 8 (80.0) Control: 4 (40.0) (SD) | Total 5 (25.0) |
Devanand, 201235 | Risperidone | 110 (80.0 years) | Intervention: 10 (25.0) Third arm: 14 (36.8) | Intervention: 25 (62.5) Control: 15 (46.9) Third arm: 21 (55.3) (SD) | Intervention: 30 (75) Control: 22 (68.8) Control: 22 (68.8) Third arm: 24 (63.2) |
Huijbers, 201618 | Maintenance antidepressant medication (specific drugs not mentioned) | 249 (50.3 years) | 68 (53.1) | Intervention: 69 (54.0) Control: 47 (38.8) | Intervention: 36 (28.1) Control: 38 (31.4) |
Ruths, 200833 | Risperidone, haloperidol, olanzapine | 55 (84.1 years) | At 4 weeks: 23 (85.2) At 2 months: 11 (40.7) At 5 months: 8 (29.6) | 2 (7.4) Stopped study medication | Intervention: 4 (14.8) Control: 3 (10.7) |
Cognitive impairment |
Gaudig, 201139 Study 1 | Galantamine | 723 (77.0 years) | 189 (95.5) | NR | Intervention: 9 (4.5) Control: 14 (6.9) Third arm: 13 (5.9) |
|
|
Study 2 | Galantamine | 118 (75.2 years) | 39 (100) | NR | Intervention: 0 Control: 1 (3.1) Third arm: 6 (12.8) |
Herrmann, 201619 | Cholinesterase inhibitor (donepezil, galantamine, rivastigmine) | 40 (89.2 years) | 15 (78.9) | Intervention: 3 (15.8) Control: 1 (4.8) | Intervention: 4 (21.1) Control: 3 (14.3) No significant difference |
Howard, 201229 | Donepezil | 295 (77.1 years) | 55 (75.3) | NR | Intervention: 18 (24.7) Control: 19 (26.0) Third arm: A: 25 (32.9) B: 15 (20.5) |
Scarpini, 201123 | Galantamine | 139 (74.5 years) | 19 (30.2) | Total study 27 (19.4), no SD between the groups according to Kaplan–Meier survival curve | Intervention: 44 (69.8) Control: 40 (52.6) |
Other |
Lee, 201226 | Tamsulosin | 69 (68.0 years) | 33 (76.7) | 2 (4.7) restarted tamsulosin again | Intervention: 10 (23.3) Control: 7 (16.3) |
Liaw, 200640 | Tamsulosin or finasteride | 78 (68.8 years) | Tamsulosin discontinuation: 28 (65.1) Finasteride discontinuation: 20 (62.5) | Tamsulosin discontinuation: 15 (35.7) Finasteride discontinuation: 12 (37.5) | 92 randomised, 18 lost to follow-up (not analysed) |
Lin, 201441 | 5ARI (Avodart, GlaxoSmithKline UK Ltd) or alpha-blocker (doxazosin) | 230 (75.3 years) | Discontinue 5ARI: 57 (48.7) Discontinue alpha-blocker: 78 (69.0) | Discontinue 5ARI: 60 (51.3) Discontinue alpha-blocker: 35 (31.0) | None |
Black, 200621 | Alendronate | 1099 (73.2 years) | 299 (68.4) | Intervention: 102 (23.3) Control: 63 (19.1) Third arm: 71 (21.3) Stopped study medication | Intervention: 138 (31.6) Control: 93 (28.3) Third arm: 109 (32.7) |
Naylor, 201024 | Raloxifene | 62 (63.4 years) | 20 (87.0) | NR | Intervention: 3 (13.0) Control: 3 (13.0) Third arm: 2 (12.5) |
Choudhury, 200725 | Fluticasone | 260 (67.5 years) | 54 (41.0) | Intervention: 78 (59.0) Control: 56 (43.7) Restarted pre-study medication | Intervention: 78 (59.0) Control: 56 (43.7) |
Wouters, 200536 | Fluticasone | 373 (63.5 years) | 138 (75.0) | NR | Intervention: 34 (18.5) Control: 46 (24.3) |
Zwisler, 201527 | Esomeprazole | 171 (59 years) | 23 (27.1) | Intervention: 58 (68.2) Control: 16 (18.6) Restarted pre-study medication (SD) | Intervention: 62 (72.9) Control: 18 (20.9) |
Boye, 201728 | Fall-risk-increasing-drugs (for specific drugs see article) | 612 (76 years) | 120 (37.6) | Of all attempted withdrawals, 35% was unsuccessful | Intervention: 11 (3.4) Control: 21 (7.2) |
Potter, 201634 | Possible inappropriate medicines | 95 (84 years) | 207 of 348 targeted medicines (59%, 4.4 ±3.4 per person) were successfully discontinued | 19% of medicines that were attempted to stop were restarted | Withdrawal failed or not attempted for 41% of the medicines selected for deprescribing |